TD Cowen raises Fortrea stock price target on margin outlook
TD Cowen raised its price target for Fortrea (NASDAQ:FTRE) to $26 from $23, citing improved margin outlook and WWCT acquisition. Shares are down 10.66% this week but up 103% year-over-year. Q3 2026 results missed estimates, but margins and cash flow improved, leading to raised 2026 guidance. Analysts from Jefferies and Truist also updated their price targets.
How this was made
The 30-second read
Why it matters
Analyst upgrades reflect confidence in margin expansion despite revenue shortfall.
Market read
New analyst price targets and guidance revisions provide fresh trading signals for FTRE.
What to watch
Potential headwinds from slower biotech spending and competitive pricing pressure.
Background
Fortrea reported Q3 2026 results that missed revenue and EPS expectations but showed better margins and cash flow.
Ticker impact
TD Cowen raised its price target on Fortrea to $26 from $23, citing improved margins and the pending WWCT acquisition.
upward pressure as investors price in higher margins and acquisition synergies
The new target reflects expectations of margin expansion and incremental benefit from the WWCT deal, which could lift the stock.
Market effects
Boosts sentiment for contract research organizations and CRO sector.
Positive impact on US biotech service providers.
Limited to U.S. markets; no immediate global ripple.
Counterpoint
The margin outlook may be overstated if WWCT integration faces delays.
Key entities
- companyFortrea Holdings Inc.
Contract research organization serving pharma and biotech.
- analystTD Cowen
Raised price target to $26 based on margin outlook.


